BenevolentAI S.A. (AMS: BAI)

Market Cap	46.34M
Revenue (ttm)	5.74M
Net Income (ttm)	-60.63M
Shares Out	121.94M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,299
Open	0.420
Previous Close	0.401
Day's Range	0.380 - 0.420
52-Week Range	0.360 - 1.410
Beta	1.07
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 20, 2024

About BenevolentAI

BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company’s development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 248
• Stock Exchange: Euronext Amsterdam
• Ticker Symbol: BAI

Financial Performance

In 2023, BenevolentAI's revenue was 7.33 million, a decrease of -30.58% compared to the previous year's 10.56 million. Losses were -63.32 million, -61.38% less than in 2022.

Financial numbers in GBP